Skip to content

Market access 2026: Germany, EU HTA, NHS value-based procurement and US reimbursement windows

What changed

Several 2026 developments materially affect future MedicalCooling market access:

  • Germany’s emergency-care reform is moving toward recognising medical emergency rescue as a distinct statutory-health-insurance service rather than merely transport.
  • The G-BA Innovationsfonds is becoming more constrained from 2027, increasing the value of remaining 2026 application windows.
  • The EU HTA framework now offers Joint Scientific Consultation pathways for selected high-risk medical devices, allowing evidence requirements to be discussed before pivotal studies.
  • The UK has strengthened value-based procurement for MedTech, putting more emphasis on outcomes, efficiency and total pathway cost rather than purchase price alone.
  • CMS continues to provide hospital new-technology payment pathways such as NTAP, while ambulance reimbursement remains a separate US workstream.

Why this matters for AIRCHILL

AIRCHILL should not generate clinical evidence first and design reimbursement evidence later. Clinical, regulatory, HTA and health-economic endpoints should be aligned from the start.

Recommended development implication

The programme should capture, where feasible:

  • neurological outcome,
  • ICU length of stay,
  • ventilation duration,
  • rehabilitation utilisation,
  • long-term care burden,
  • device and consumable cost,
  • EMS workflow time and staffing,
  • hospital resource use.

This enables one evidence programme to support clinical validation, CE/FDA strategy, HTA, procurement and payer discussions.

Primary institutions to monitor: German Bundestag/BMG, G-BA, European Commission HTA Coordination Group, NICE/NHS, CMS.

AIRCHILL remains a development-stage technology and no reimbursement pathway described here constitutes current coverage for AIRCHILL.